CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
14 déc. 2020 08h07 HE
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
05 mars 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Thursday, March 12 at 8:30 a.m. ET - Norwood, MA, March 05, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
18 nov. 2019 08h17 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
08 août 2019 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Clinical development of lenabasum on target for 2020 data readouts in lead indications systemic sclerosis and cystic fibrosis; diseases affect ~270,000 people total in U.S., EU and Japan CRB-4001 on...
Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
11 mars 2019 08h35 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Presentation with live audio webcast on Tuesday, March 19, 2019 at 2:10 p.m. ET- Norwood, MA, March 11, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November
06 nov. 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT – – 30th Annual Piper Jaffray Healthcare Conference presentation with...
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
06 juin 2018 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
24 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
22 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
15 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented - Norwood, MA, May 15,...